Kurowski Michael, Kaeser B, Sawyer A, Popescu M, Mroziekiewicz A, Arslan A, Staszewski S
Therapia GmbH, c/o Auguste Viktoria Krankenhaus, Immunologische Tagesklinik, Rubensstr. 125, 12157 Berlin, Germany.
Eur J Med Res. 2002 Oct 29;7(10):453-6.
The objective of the study was to investigate the effect of two different breakfasts on the pharmacokinetics of nelfinavir under steady state conditions.
Twenty-four healthy male volunteers were evaluated in a 17 days open labeled one sequence crossover study evaluating the effect of a 'light' breakfast (350 kcal) compared to a standard breakfast (800 kcal) on the pharmacokinetics of nelfinavir at steady state during 1250 mg twice daily (BID) administration.
After administration with a standard breakfast higher concentrations of nelfinavir were observed during the terminal phase than after administration with a 'light' breakfast. The comparison of the log subset 10 transformed parameters C subset 1-hr-postdose, AUC subset 0-12h, C subset max, and C subset 12 hours, showed that the AUC subset 0-12h was decreased by 13% (P = 0.01) after administration with the 'light' breakfast. Nelfinavir 1250 mg BID was well tolerated.
Although drug intake with a 'light' breakfast' showed a statistically significant decrease for nelfinavir AUC subset 0-12h, this marginal 13% reduction is not considered clinically relevant. No significant effects of the two different breakfasts were found for the remaining three parameters tested C subset 1-hr-postdose, C subset max, and C subset 12 hours.
本研究的目的是在稳态条件下研究两种不同早餐对奈非那韦药代动力学的影响。
在一项为期17天的开放标签单序列交叉研究中,对24名健康男性志愿者进行了评估,该研究比较了“清淡”早餐(350千卡)与标准早餐(800千卡)对奈非那韦在每日两次(BID)服用1250毫克稳态时药代动力学的影响。
与服用“清淡”早餐后相比,服用标准早餐后在终末相观察到更高的奈非那韦浓度。对log子集10转换后的参数给药后1小时C子集、0至12小时AUC子集、C子集最大值和12小时C子集进行比较,结果显示服用“清淡”早餐后0至12小时AUC子集降低了13%(P = 0.01)。每日两次服用1250毫克奈非那韦耐受性良好。
尽管服用“清淡”早餐时药物摄入使奈非那韦0至12小时AUC子集有统计学意义的降低,但这13%的微小降低在临床上不被认为具有相关性。对于其余三个测试参数给药后1小时C子集、C子集最大值和12小时C子集,未发现两种不同早餐有显著影响。